EGFR-vIII and MSS-specific CRC enriched in AdenoSig and unique Spp1 high TAM in mCRPC, showed a likelihood of benefits from the rational combination with A2AR inhibitors. This evidence concerns the gene EGFR and colorectal carcinoma.